Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Cidara Therapeutics Inc. Revenue & Financial Statements
Cidara Therapeutics Inc. reported revenue of $1.3M for the fiscal year ended December 31, 2024, down 70.6% year over year, with net income of $(169.8M) and diluted EPS of $-26.75.
- Company
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2024
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 4.3M | 1.3M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | (71.8M) | (42.3M) | (29.7M) | (24.5M) | (176.1M) |
| Pretax income | — | — | (29.5M) | (22.5M) | (170.3M) |
| Net income | (72.1M) | (42.5M) | (29.8M) | (22.9M) | (169.8M) |
| Diluted EPS | — | -0.81 | -0.43 | -0.26 | -26.75 |
| EBITDA | (71.6M) | (42.1M) | (29.6M) | (24.4M) | (175.9M) |
Quarterly
| USD | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9M | 2.8M | 302K | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | (6.1M) | (10.7M) | (96.0M) | (17.4M) | (54.2M) | (25.3M) | (27.4M) | (88.6M) |
| Pretax income | (5.5M) | — | (94.2M) | (15.5M) | (52.4M) | — | — | — |
| Net income | (5.6M) | (10.3M) | (91.2M) | (16.0M) | (52.3M) | (23.5M) | (25.7M) | (83.3M) |
| Diluted EPS | -0.06 | -2.28 | -19.99 | -2.45 | -4.22 | -1.66 | -1.65 | -3.10 |
| EBITDA | (6.0M) | (10.7M) | — | (17.4M) | (54.1M) | (25.2M) | — | (88.6M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Total assets | 60.4M | 75.3M | 47.6M | 67.0M | 214.8M |
| Current assets | 57.2M | 71.7M | 45.1M | 60.9M | 210.7M |
| Cash & equivalents | 35.9M | 59.7M | 32.7M | 35.8M | 189.8M |
| Total liabilities | 49.7M | 53.8M | 50.5M | 75.2M | 51.5M |
| Current liabilities | 38.6M | 34.0M | 30.0M | 67.4M | 49.6M |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | 10.7M | 21.6M | (2.9M) | (8.2M) | 163.3M |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Operating cash flow | (54.4M) | (25.2M) | (28.5M) | (22.4M) | (176.5M) |
| Investing cash flow | (186K) | (41K) | (118K) | (505K) | (129K) |
| Financing cash flow | 37.3M | 44.6M | (951K) | 26.0M | 337.1M |
| Capital expenditure | 186K | 41K | 118K | 505K | 129K |
| Free cash flow | (54.6M) | (25.3M) | (28.6M) | (22.9M) | (176.7M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 4.1M | 4.0M | 3.5M | 3.1M | 3.9M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every CDTX filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.